Sareum today announced the dosing of the first subjects in the food effects part of its Phase 1a clinical trial of lead programme SDC-1801. The food effects study is designed to determine how the presence of food might affect the absorption and pharmacokinetic profile of SDC-1801. This will inform whether the drug should be taken with food or on an empty stomach, optimising its potential benefits whilst potentially minimising any possible side effects. This study runs in conjunction with the Sin ....
